臨床婦人科産科77巻2号

2023年03月発行

今月の臨床 子宮体がん診療の最前線―最新分類から治療法まで

薬物療法

子宮体部肉腫の分子標的療法

著者： 河村美由紀¹

所属機関： ¹兵庫県立がんセンター腫瘍内科

ページ範囲：P.306 - P.312

文献概要

●子宮肉腫には多様な組織型があり，それぞれの標準治療は確立していない．最も多い組織型である子宮平滑筋肉腫も，ドキソルビシン療法以降の治療法は確立していない．

●子宮内膜間質肉腫（ESS）は，低異型度ESS・高異型度ESS・未分化子宮肉腫に分類される．低異型度ESSはホルモン療法の効果が報告されているが，高異型度ESSや未分化子宮肉腫に確立した治療はない．

●子宮がん肉腫は，子宮体がんに準じて扱われているが，HER2陽性割合が高いなど特殊な組織型である．国内第Ⅱ相試験であるSTATICE試験でT-Dxdの高い効果を認めた．

参考文献

1）Clarke MA, et al : Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers. J Clin Oncol 37 : 1895-1908, 2019

2）Tropé CG, et al : Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol 51 : 694-705, 2012

3）Hensley ML, et al : Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma : results of a phase II trial. J Clin Oncol 20 : 2824-2831, 2002

4）Hensley ML, et al : Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma : a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109 : 329-334, 2008

5）Hensley ML, et al : Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma : a Gynecologic Oncology Group phase II study. Gynecol Oncol 109 : 323-328, 2008

6）Seddon B, et al : Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas（GeDDiS）: a randomised controlled phase 3 trial. Lancet Oncol 18 : 1397-1410, 2017

7）日本整形外科学会診療ガイドライン委員会，他（編） : 軟部腫瘍診療ガイドライン2020（改訂第3版）．南江堂，2020

8）日本婦人科腫瘍学会（編） : 子宮体がん治療ガイドライン，2018年版．金原出版，2018

9）Demetri GD, et al : Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy : results of a phase III randomized multicenter clinical trial. J Clin Oncol 34 : 786-793, 2016

10）Hensley ML, et al : Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy : subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol 146 : 531-537, 2017

11）Schöffski P, et al : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet 387 : 1629-1637, 2016

12）Blay JY, et al : Eribulin versus dacarbazine in patients with leiomyosarcoma : subgroup analysis from a phase 3, open-label, randomised study. Br J Cancer 120 : 1026-1032, 2019

13）van der Graaf WT, et al : Pazopanib for metastatic soft-tissue sarcoma（PALETTE） : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012

14）Cesne AL, et al : Safety and efficacy of pazopanib in advanced soft tissue sarcoma : PALETTE（EORTC 62072） subgroup analyses. BMC Cancer 19 : 794, 2019

15）Benson C, et al : Outcome of uterine sarcoma patients treated with pazopanib : a retrospective analysis based on two European Organisation for Research and Treatment of Cancer（EORTC） Soft Tissue and Bone Sarcoma Group（STBSG） clinical trials 62043 and 62072. Gynecol Oncol 142 : 89-94, 2016

16）Chudasama P, et al : Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun 9 : 144, 2018

17）Seligson ND, et al : BRCA1/2 functional loss defines a targetable subset in leiomyosarcoma. Oncologist 24 : 973-979, 2019

18）Ingham M, et al : NCI protocol 10250 : a phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma. 2021 ASCO Annual Meeting I. J Clin Oncol 38（suppl） : 11506, 2021

19）Asano H, et al : Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency（JGOG2052）. J Gynecol Oncol 33 : e55, 2022

20）Ben-Ami E, et al : Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus : Results of a phase 2 study. Cancer 123 : 3285-3290, 2017

21）Lagos G, et al : Large scale multi-omic analysis suggests mechanisms of resistance to immunotherapy in leiomyosarcoma. 2021 ASCO Annual Meeting I. J Clin Oncol 39（suppl） : 11512, 2021

22）Altman AD, et al : Uterine sarcoma and aromatase inhibitors : Tom Baker Cancer Centre experience and review of the literature. Int J Gynecol Cancer 22 : 1006-1012, 2012

23）Pink D, et al : Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma : single center experience with 10 cases and review of the literature. Gynecol Oncol 101 : 464-469, 2006

24）Crowley F, et al : Evaluating the role of aromatase inhibitors（AIs） in the treatment of endometrial stromal sarcomas（ESS）. 2021 ASCO Annual Meeting I. J Clin Oncol 39（suppl） : 5575, 2021

25）Wade K, et al : Uterine sarcoma : steroid receptors and response to hormonal therapy. Gynecol Oncol 39 : 364-367, 1990

26）Sutton G, et al : Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy : a study of the Gynecologic Oncology Group. Obstet Gynecol 87 : 747-750, 1996

27）Salvatierra A, et al : A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate. Gynecol Oncol 101 : 545-547, 2006

28）Verschoor AJ, et al : A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report. BMC Cancer 18 : 92, 2018

29）Ou WB, et al : YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways. Oncogenesis 10 : 37, 2021

30）Kommoss FKF, et al : DNA methylation-based profiling of uterine neoplasms : a novel tool to improve gynecologic cancer diagnostics. J Cancer Res Clin Oncol 146 : 97-104, 2020

31）Matsuo K, et al : Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol 27 : 1257-1266, 2016

32）Sutton G, et al : A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus : a Gynecologic Oncology Group Study. Gynecol Oncol 79 : 147-153, 2000

33）Homesley HD, et al : Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma : a Gynecologic Oncology Group Study. J Clin Oncol 25 : 526-531, 2007

34）Powell MA, et al : Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus : a Gynecologic Oncology Group study. J Clin Oncol 28 : 2727-2731, 2010

35）Powell MA, et al : randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and ifosfamide in patients with carcinosarcoma of the uterus or ovary : an NRG oncology trial. J Clin Oncol 40 : 968-977, 2022

36）Sawada M, et al : Different expression patterns of KIT, EGFR, and HER-2（c-erbB-2）oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci 94 : 986-991, 2003

37）Yoshida H, et al : Histopathological features of HER2 overexpression in uterine carcinosarcoma : proposal for requirements in HER2 testing for targeted therapy. Virchows Arch 478 : 1161-1171, 2021

38）Hasegawa K, et al : Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma（STATICE TRIAL, NCCH1615） : a multicenter, phase II Clinical trial. Ann Oncol 32（suppl 5） : S767, 2021

39）Matsuzaki S, et al : Uterine carcinosarcoma : contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol 160 : 586-601, 2021